Veeva Systems (VEEV) Stock News, Jun-Aug 2025

Veeva Systems (NYSE:VEEV) and IQVIA (NYSE:IQV) have announced comprehensive global partnerships in clinical and commercial domains, alongside resolving all pending legal disputes. The long-term agreement enables seamless integration of both companies' software, data, technology, and services.

The commercial partnership establishes master data and third-party access agreements, allowing mutual data usage across platforms including Veeva Network, Veeva Nitro, and Veeva AI. IQVIA has joined multiple Veeva partner programs to support customer integrations. In the clinical domain, IQVIA's participation in Veeva's CRO Clinical Data Partner program will facilitate clinical trials execution using Veeva's software products, particularly in EDC (Electronic Data Capture) implementations.

Veeva Systems (NYSE:VEEV) released its 2025 MedTech Clinical Benchmark report, revealing key trends in medical technology clinical operations. The study shows that 68% of medtech teams prioritize reducing manual processes in site collaboration, while 56% focus on study quality improvement.

The report highlights significant gaps in technology adoption, with only 14% of large medtechs (>$1B revenue) and 24% of smaller companies having site collaboration tools. Additionally, 72% of organizations plan to invest in AI/ML infrastructure, while 58% will prioritize data collection and cleaning in the coming year.

Key challenges identified include on-time data entry, document exchange, and monitoring compliance, with manual processes (32%), global trial regulation compliance (18%), and inspection readiness (18%) being the top hurdles.

Veeva Systems (NYSE: VEEV) has scheduled its fiscal 2026 second quarter financial results announcement for August 27, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results.

Prepared remarks will be available on Veeva's investor relations website at approximately 1:05 p.m. PT. Investors can access the conference call through registration and follow the webcast on ir.veeva.com. A replay of the webcast will be available following the event.

Veeva Systems (NYSE:VEEV) released its 2025 Medtech Regulatory Affairs Benchmark report, revealing significant challenges in regulatory data quality and processes. The study found that 50% of respondents lack full confidence in their global product registration data, while only 17% rate their regulatory data quality as excellent.

Key findings show that 80% of respondents take a month or longer to prepare 510(k) submissions, with 24% requiring over six months. Only 5% use fully automated time-to-market monitoring, while 67% rely on manual processes. Major operational challenges include administrative burden (61%), siloed processes (49%), and digital tool proficiency (35%).

To address these challenges, 56% of organizations plan to adopt regulatory information management systems, while 52% aim to develop system integrations.

Veeva Systems (NYSE:VEEV) announced that Boehringer Ingelheim, a top 20 biopharma company, will standardize its customer data across more than 100 countries using Veeva OpenData and Veeva Network solutions.

The implementation will provide Boehringer Ingelheim's teams with accurate customer reference data to engage healthcare professionals (HCPs) more effectively and create a foundation for AI scaling. The consolidation to a single comprehensive solution will simplify data management and improve cross-team collaboration through standardized, high-quality customer data access.

The integration with Veeva Vault CRM will be streamlined through native OpenData and Network connections, supporting Boehringer's commercial excellence and AI initiatives.

Veeva Systems (NYSE: VEEV) announced that Merck (NYSE: MRK) has committed to implementing Veeva Vault CRM to support their upcoming product launches across multiple therapeutic areas. The partnership expansion highlights Merck's strategic decision to leverage Vault CRM for enhanced commercial execution.

Vault CRM, part of the Vault CRM Suite, offers deep applications for commercial execution across personal and digital channels, featuring advanced global capabilities to address region-specific business and compliance requirements. This technology adoption comes at a crucial time as Merck prepares for one of its most significant launch periods in company history.

Amazon Web Services (NASDAQ: AMZN) and Veeva Systems (NYSE: VEEV) announced an expansion of their 10-year partnership. Veeva is utilizing AWS's cloud infrastructure for over 50 Veeva Vault applications and specialized data offerings, including Veeva Vault CRM Suite, Veeva Compass, and Veeva CRM Pulse.

The collaboration deepens with Veeva's integration of Amazon Connect into Vault CRM Service Center for enhanced customer service operations. Additionally, AWS has joined Veeva's AI Partner program to support their artificial intelligence strategy and enable mutual customer success.

Veeva Systems (NYSE: VEEV) announced significant adoption of its clinical platform applications in the medtech industry, with over 50 medtech companies, including 11 of the top 20, now using their solutions. The company's MedTech platform is helping streamline medical device and diagnostics studies, with customers reporting impressive efficiency gains. Notable achievements include 50% faster study build times with Veeva EDC and 80% reductions in duplicate trial documents with Veeva eTMF. Key customer testimonials highlight significant improvements: Alcon achieved 50% standardization in one year, LifeNet Health reported enhanced regulatory compliance, and Smith+Nephew reduced quality control time by over 90%. The platform helps companies maintain compliance with local, regional, and global regulations while providing scalability for growth.

A new Veeva MedTech study reveals that 88% of medtech companies plan to modernize their postmarket quality management within three years. The 2025 benchmark report, surveying over 100 quality leaders, shows that 68% still rely on manual or legacy systems, potentially causing delays in addressing product issues. Key findings indicate that 38% of companies prioritize proactive and risk-based quality management, while 26% focus on scaling processes for growth. 75% believe advanced technology can drive automation for efficiency, and 62% see value in connecting quality management processes. However, emerging technologies like AI and automation show limited adoption at less than 3%. The study also highlights a significant training gap, with only 19% of respondents confident in their current training programs for postmarket quality teams.